VANCOUVER, British Columbia, Sept. 1, 2022 (GLOBE NEWSWIRE) — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and associates in Israel, is pleased to announce that it has signed a distribution agreement for Praesidio Health (Praesidio) products with Pure Integrative Pharmacy (PURE).
“I am pleased to announce our first executed distribution agreement in Canada,” said CEO Phil Floucault. “The Praesidio team has worked hard to bring our NPN formulations forward and get them into the hands of consumers. Pure Integrative Pharmacy, with their commitment to evidence-based complementary medicines and cutting-edge products, is a perfect match for Praesidio Health products. This is the first step in delivering on our promise to our shareholders to have products on the market by the fourth quarter of 2022. We are very pleased to be working with the PURE team and see this contract as the catalyst for the expanding our distribution network not only in Canada, but throughout North America.”
Pure Integrative Pharmacy includes 17 locations in British Columbia, Canada. Originally founded to challenge the community pharmacy status quo, PURE works to bridge the gap between conventional and complementary medicine and become an integrative and accessible health center for their customers. Focusing on evidence-based efficacy and safety, PURE strives to bring together the best of conventional and complementary medicine to empower clients to take control of their health.
Praesidio develops natural health products (“NRPs”) using an evidence-based process. Praesidio, a pioneer in NHPs and therapies, is actively developing several NHP candidates for use in a range of conditions, including post-viral exposure prophylaxis, urology, anxiety/stress, immune boosting and sleep aids. Praesidio has submitted all first round product formulations to Health Canada for review and approval as natural health products.
On behalf of the Board of Directors
Chief Executive Officer and President
About Israel Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF)
Isracann is a multidisciplinary cannabis-focused producer and product developer with Israeli-based cannabis production farms and a Canadian natural medicine development and manufacturing division. Simultaneously targeting the first retail sales in Canada and by becoming a leading cannabis producer offering low-cost domestic Israeli production, the company aims to commercialize natural health drugs in Canada and exploit agreements within Israel for import/export opportunities and medical marijuana cultivation. For more information, visit: www.isracann.com.
Empire Communications Group
+1 (604) 343-2724
This press release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects”, “potential” and similar expressions, or that events or circumstances “will”, “should”, “may”, “could” or “should” occur. Forward-looking statements may include, without limitation, statements regarding the company bringing products to market in the fourth quarter of 2022 and the company’s plans to expand its distribution network in Canada and North America. The forward-looking statements in this press release are expressly qualified in their entirety by this cautionary statement. All forward-looking statements in this press release are made as of the date of this press release. The forward-looking statements in this document are also generally subject to assumptions and risks and uncertainties described from time to time in the company’s filings from time to time with the CSE, the British Columbia Securities Commission, the Alberta Securities Commission and the Ontario Securities Commission. While Isracann believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Isracann expressly disclaims any intent or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The CSE assumes no responsibility for the suitability or accuracy of this release.